- Boris Jordan, Chairman of Curaleaf, shares insights on the politics of the cannabis industry, including the recent recommendation by the Health and Human Services Department to the DEA about cannabis rescheduling.
- He will be further discussing these views at the upcoming Benzinga Cannabis Capital Conference.
In recent years, the cannabis industry has swiftly moved to the center of numerous political debates. As legislative progress, such as the recent recommendation by the Health and Human Services Department (HHS), creates new possibilities for the industry, leading voices from the field, like Boris Jordan, Chairman of Curaleaf, are paying keen attention.
In an exclusive exchange with Benzinga, Jordan offers an informed perspective on the HHS's advice to the Drug Enforcement Administration (DEA) regarding cannabis rescheduling. His insights stem from a profound understanding of this high-growth sector, augmented by his role at the helm of Curaleaf, a leading player in the industry.
According to Jordan, the HHS's recommendation represents a huge step forward for the cannabis industry, signifying potential alterations in legislation that can enable its further development. "This is an anticipated event that we've been looking forward to, especially with the current administration's support for reevaluating the status of cannabis," he elucidates.
Comments